HRP20000895A2 - 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives - Google Patents

2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives Download PDF

Info

Publication number: HRP20000895A2
Authority: HR; Croatia
Prior art keywords: ethylamino; tetrahydro; purin; furan; ethyl
Prior art date: 1998-06-23

Application number

HR20000895A

Other languages

English (en)

Croatian (hr)

Inventor

David George Allen

David Edmund Bays

Chuen Chan

Caroline Mary Coox

Richard Peter Charles Cousins

Brian Cox

Hazel Joan Dyke

Frank Ellis

Joana Victoria Geden

Heather Hobbs

Alison Judith Redgrave

Stephen Swanson

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-23

Filing date

2000-12-21

Publication date

2001-10-31

2000-12-21 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2001-10-31 Publication of HRP20000895A2 publication Critical patent/HRP20000895A2/hr

Links

YQUJSBYIKMQCIT-UHFFFAOYSA-N 2-purin-9-yloxolane-3,4-diol Chemical class OC1C(O)COC1N1C2=NC=NC=C2N=C1 YQUJSBYIKMQCIT-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 182
239000000203 mixture Substances 0.000 claims description 80
-1 ethyl-piperidin-1-yl Chemical group 0.000 claims description 39
238000000034 method Methods 0.000 claims description 35
238000002360 preparation method Methods 0.000 claims description 30
150000003839 salts Chemical class 0.000 claims description 24
229910052757 nitrogen Inorganic materials 0.000 claims description 23
238000006243 chemical reaction Methods 0.000 claims description 21
238000011282 treatment Methods 0.000 claims description 18
239000001257 hydrogen Substances 0.000 claims description 15
229910052739 hydrogen Inorganic materials 0.000 claims description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
239000012453 solvate Chemical class 0.000 claims description 14
125000003118 aryl group Chemical group 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
125000000217 alkyl group Chemical group 0.000 claims description 11
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 11
229910052736 halogen Inorganic materials 0.000 claims description 9
150000002367 halogens Chemical class 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
239000000825 pharmaceutical preparation Substances 0.000 claims description 8
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
229910052760 oxygen Inorganic materials 0.000 claims description 7
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
229910052717 sulfur Inorganic materials 0.000 claims description 6
208000006673 asthma Diseases 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
125000002785 azepinyl group Chemical group 0.000 claims description 4
125000002393 azetidinyl group Chemical group 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
125000002757 morpholinyl group Chemical group 0.000 claims description 4
125000004193 piperazinyl group Chemical group 0.000 claims description 4
125000003386 piperidinyl group Chemical group 0.000 claims description 4
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
229910005965 SO 2 Inorganic materials 0.000 claims description 3
125000002877 alkyl aryl group Chemical group 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
125000004076 pyridyl group Chemical group 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
KQYAZOONHVDJEU-CKXMCULTSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-morpholin-4-ylethylamino)purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)oxolane-3,4-diol Chemical compound O1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCN4CCOCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 KQYAZOONHVDJEU-CKXMCULTSA-N 0.000 claims 1
NOYRFHBSCWDJGK-CKXMCULTSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-morpholin-4-ylethylamino)purin-9-yl]-5-(5-ethyl-1h-1,2,4-triazol-3-yl)oxolane-3,4-diol Chemical compound N1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCN4CCOCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 NOYRFHBSCWDJGK-CKXMCULTSA-N 0.000 claims 1
GYOMGLACOXBHTA-KCIBBDPESA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]-5-(1-ethyl-1,2,4-triazol-3-yl)oxolane-3,4-diol Chemical compound CCN1C=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCN4CCCCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 GYOMGLACOXBHTA-KCIBBDPESA-N 0.000 claims 1
MWAFNAFZJUAOKP-KCIBBDPESA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)oxolane-3,4-diol Chemical compound O1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCN4CCCCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 MWAFNAFZJUAOKP-KCIBBDPESA-N 0.000 claims 1
SBBAFENCIRVCTC-KCIBBDPESA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-pyridin-2-ylethylamino)purin-9-yl]-5-(1-ethyl-1,2,4-triazol-3-yl)oxolane-3,4-diol Chemical compound CCN1C=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCC=4N=CC=CC=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 SBBAFENCIRVCTC-KCIBBDPESA-N 0.000 claims 1
NVHPRHDQZLXVMD-KCIBBDPESA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-pyridin-2-ylethylamino)purin-9-yl]-5-(5-ethyl-1h-1,2,4-triazol-3-yl)oxolane-3,4-diol Chemical compound N1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCC=4N=CC=CC=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 NVHPRHDQZLXVMD-KCIBBDPESA-N 0.000 claims 1
KUUDGUNZYGRNCR-OVDFTCDZSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-pyrrolidin-1-ylethylamino)purin-9-yl]-5-(5-methyl-1h-1,2,4-triazol-3-yl)oxolane-3,4-diol Chemical compound N1C(C)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCN4CCCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 KUUDGUNZYGRNCR-OVDFTCDZSA-N 0.000 claims 1
ONRVDWDGXWNIJE-CKXMCULTSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-[2-(1-methylimidazol-4-yl)ethylamino]purin-9-yl]-5-(1-ethyl-1,2,4-triazol-3-yl)oxolane-3,4-diol Chemical compound CCN1C=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCC=4N=CN(C)C=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 ONRVDWDGXWNIJE-CKXMCULTSA-N 0.000 claims 1
VFTYMVGNRQUSLP-CKXMCULTSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-[2-(1-methylimidazol-4-yl)ethylamino]purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)oxolane-3,4-diol Chemical compound O1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCC=4N=CN(C)C=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 VFTYMVGNRQUSLP-CKXMCULTSA-N 0.000 claims 1
ABGLUDPUGYNORO-OVDFTCDZSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-[2-(1-methylimidazol-4-yl)ethylamino]purin-9-yl]-5-(5-methyl-1h-1,2,4-triazol-3-yl)oxolane-3,4-diol Chemical compound N1C(C)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCC=4N=CN(C)C=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 ABGLUDPUGYNORO-OVDFTCDZSA-N 0.000 claims 1
FTTFQEJMJMISPK-UMHHXCEVSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-[[(1r)-1-hydroxy-2-phenylethyl]amino]purin-9-yl]-5-(1-ethyl-1,2,4-triazol-3-yl)oxolane-3,4-diol Chemical compound CCN1C=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(N[C@H](O)CC=4C=CC=CC=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 FTTFQEJMJMISPK-UMHHXCEVSA-N 0.000 claims 1
XOJTXESFIREACI-KKPNIWNPSA-N (2r,3r,4s,5s)-2-[2-(2-cyclohexylethylamino)-6-(pentan-3-ylamino)purin-9-yl]-5-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](O)[C@H](O3)C=3OC(=NN=3)C3CC3)O)C=NC=2C(NC(CC)CC)=NC=1NCCC1CCCCC1 XOJTXESFIREACI-KKPNIWNPSA-N 0.000 claims 1
SMDOIHWEEKGWKA-DDOIHHOZSA-N (2r,3r,4s,5s)-2-[2-(cyclopentylamino)-6-(pentan-3-ylamino)purin-9-yl]-5-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](O)[C@H](O3)C=3OC(=NN=3)C3CC3)O)C=NC=2C(NC(CC)CC)=NC=1NC1CCCC1 SMDOIHWEEKGWKA-DDOIHHOZSA-N 0.000 claims 1
LBMWOLNCFALFJL-CKXMCULTSA-N (2r,3r,4s,5s)-2-[6-(2,2-diphenylethylamino)-2-(2-morpholin-4-ylethylamino)purin-9-yl]-5-(5-ethyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol Chemical compound O1C(CC)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(NCCN4CCOCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 LBMWOLNCFALFJL-CKXMCULTSA-N 0.000 claims 1
ARYQGKOGXSGCDO-KCIBBDPESA-N (2r,3r,4s,5s)-2-[6-(2,2-diphenylethylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]-5-(5-ethyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol Chemical compound O1C(CC)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(NCCN4CCCCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 ARYQGKOGXSGCDO-KCIBBDPESA-N 0.000 claims 1
BDMOZOVOLGZNNS-CKXMCULTSA-N (2r,3r,4s,5s)-2-[6-(2,2-diphenylethylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]-5-(5-methyl-1,3,4-thiadiazol-2-yl)oxolane-3,4-diol Chemical compound S1C(C)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(NCCN4CCCCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 BDMOZOVOLGZNNS-CKXMCULTSA-N 0.000 claims 1
ZBWRIVJLEVKESA-KCIBBDPESA-N (2r,3r,4s,5s)-2-[6-(2,2-diphenylethylamino)-2-(2-pyridin-2-ylethylamino)purin-9-yl]-5-(5-ethyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol Chemical compound O1C(CC)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(NCCC=4N=CC=CC=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 ZBWRIVJLEVKESA-KCIBBDPESA-N 0.000 claims 1
LTIWXZXNIPUQLP-OVDFTCDZSA-N (2r,3r,4s,5s)-2-[6-(2,2-diphenylethylamino)-2-[2-(1-methylimidazol-4-yl)ethylamino]purin-9-yl]-5-(5-methyl-1,3,4-thiadiazol-2-yl)oxolane-3,4-diol Chemical compound S1C(C)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(NCCC=4N=CN(C)C=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 LTIWXZXNIPUQLP-OVDFTCDZSA-N 0.000 claims 1
FWMSWNOTFXTHAH-IYXIZZNPSA-N (2r,3s,4r,5r)-2-(5-ethyl-1,2-oxazol-3-yl)-5-[6-(pentan-3-ylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]oxolane-3,4-diol Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](O)[C@H](O3)C3=NOC(CC)=C3)O)C=NC=2C(NC(CC)CC)=NC=1NCCN1CCCCC1 FWMSWNOTFXTHAH-IYXIZZNPSA-N 0.000 claims 1
WWAGALBNJHQBSV-UAKAABGRSA-N (2s,3s,4r,5r)-2-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-5-[2-[2-(1-methylimidazol-4-yl)ethylamino]-6-(pentan-3-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](O)[C@H](O3)C=3OC(=NN=3)C3CC3)O)C=NC=2C(NC(CC)CC)=NC=1NCCC1=CN(C)C=N1 WWAGALBNJHQBSV-UAKAABGRSA-N 0.000 claims 1
QXHRLRFYERUHFZ-LKPCVQNHSA-N N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN(C=N1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN(C=N1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 QXHRLRFYERUHFZ-LKPCVQNHSA-N 0.000 claims 1
AYHREVIVPMZMBX-DIFXNMBTSA-N N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)C(C)C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)C(C)C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 AYHREVIVPMZMBX-DIFXNMBTSA-N 0.000 claims 1
RADOIHHZEXMYJY-FJUNXPAFSA-N N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 RADOIHHZEXMYJY-FJUNXPAFSA-N 0.000 claims 1
MMVJRBFCIPIVJZ-CUCOOGOQSA-N N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 MMVJRBFCIPIVJZ-CUCOOGOQSA-N 0.000 claims 1
PMPLSBZLYAIIHY-CUCOOGOQSA-N N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NOC(=N1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NOC(=N1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 PMPLSBZLYAIIHY-CUCOOGOQSA-N 0.000 claims 1
HHQZWAIXIRCHHU-QTHPYMFXSA-N N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C=1OC(=NN1)C1CC1)NC(CC)CC Chemical compound N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C=1OC(=NN1)C1CC1)NC(CC)CC HHQZWAIXIRCHHU-QTHPYMFXSA-N 0.000 claims 1
QPCYORFPDMILHA-CUCOOGOQSA-N N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C=1OC(=NN1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C=1OC(=NN1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 QPCYORFPDMILHA-CUCOOGOQSA-N 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 208
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 98
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 94
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
239000000243 solution Substances 0.000 description 76
239000007787 solid Substances 0.000 description 69
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 62
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 52
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
239000000377 silicon dioxide Substances 0.000 description 43
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 42
238000004108 freeze drying Methods 0.000 description 39
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 36
238000004128 high performance liquid chromatography Methods 0.000 description 32
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
239000002904 solvent Substances 0.000 description 28
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 27
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 27
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
229910052681 coesite Inorganic materials 0.000 description 26
229910052906 cristobalite Inorganic materials 0.000 description 26
235000012239 silicon dioxide Nutrition 0.000 description 26
229910052682 stishovite Inorganic materials 0.000 description 26
238000004809 thin layer chromatography Methods 0.000 description 26
229910052905 tridymite Inorganic materials 0.000 description 26
238000007670 refining Methods 0.000 description 25
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 22
239000011541 reaction mixture Substances 0.000 description 22
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
229910052943 magnesium sulfate Inorganic materials 0.000 description 21
235000019341 magnesium sulphate Nutrition 0.000 description 21
210000000265 leukocyte Anatomy 0.000 description 18
239000000126 substance Substances 0.000 description 18
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
238000003756 stirring Methods 0.000 description 16
238000000746 purification Methods 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 14
239000012074 organic phase Substances 0.000 description 14
239000003921 oil Substances 0.000 description 13
235000019198 oils Nutrition 0.000 description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
239000012299 nitrogen atmosphere Substances 0.000 description 12
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 11
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
239000002585 base Substances 0.000 description 11
238000004587 chromatography analysis Methods 0.000 description 11
235000019253 formic acid Nutrition 0.000 description 11
235000017557 sodium bicarbonate Nutrition 0.000 description 11
229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
239000012267 brine Substances 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
230000000694 effects Effects 0.000 description 10
238000010828 elution Methods 0.000 description 10
239000006260 foam Substances 0.000 description 10
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
239000008346 aqueous phase Substances 0.000 description 9
235000019441 ethanol Nutrition 0.000 description 9
239000002126 C01EB10 - Adenosine Substances 0.000 description 8
229960005305 adenosine Drugs 0.000 description 8
VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 8
201000010099 disease Diseases 0.000 description 8
238000002414 normal-phase solid-phase extraction Methods 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 8
230000009471 action Effects 0.000 description 7
238000004440 column chromatography Methods 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
239000012044 organic layer Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
230000000451 tissue damage Effects 0.000 description 7
231100000827 tissue damage Toxicity 0.000 description 7
108050000203 Adenosine receptors Proteins 0.000 description 6
102000009346 Adenosine receptors Human genes 0.000 description 6
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
229960000583 acetic acid Drugs 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000004913 activation Effects 0.000 description 6
239000000556 agonist Substances 0.000 description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
239000012043 crude product Substances 0.000 description 6
CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
239000003480 eluent Substances 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
238000010992 reflux Methods 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
MLIQNIZEXDTMLL-SEDAZVQISA-N (3ar,4r,6s,6as)-4-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxylic acid Chemical compound N1=C(Cl)N=C2N([C@H]3[C@H]4[C@@H]([C@H](O3)C(O)=O)OC(O4)(C)C)C=NC2=C1NCC(C=1C=CC=CC=1)C1=CC=CC=C1 MLIQNIZEXDTMLL-SEDAZVQISA-N 0.000 description 5
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 5
CJNRGSHEMCMUOE-UHFFFAOYSA-N 2-piperidin-1-ylethanamine Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
FHQDWPCFSJMNCT-UHFFFAOYSA-N N(tele)-methylhistamine Chemical compound CN1C=NC(CCN)=C1 FHQDWPCFSJMNCT-UHFFFAOYSA-N 0.000 description 5
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
230000003110 anti-inflammatory effect Effects 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
230000008020 evaporation Effects 0.000 description 5
230000004968 inflammatory condition Effects 0.000 description 5
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
239000000843 powder Substances 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
239000000725 suspension Substances 0.000 description 5
125000001425 triazolyl group Chemical group 0.000 description 5
NGXSWUFDCSEIOO-SCSAIBSYSA-N (3r)-pyrrolidin-3-amine Chemical compound N[C@@H]1CCNC1 NGXSWUFDCSEIOO-SCSAIBSYSA-N 0.000 description 4
STVVMTBJNDTZBF-VIFPVBQESA-N L-phenylalaninol Chemical compound OC[C@@H](N)CC1=CC=CC=C1 STVVMTBJNDTZBF-VIFPVBQESA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
150000003835 adenosine derivatives Chemical class 0.000 description 4
239000008365 aqueous carrier Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000012230 colorless oil Substances 0.000 description 4
239000006071 cream Substances 0.000 description 4
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
238000002953 preparative HPLC Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 3
RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 3
XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
101150051188 Adora2a gene Proteins 0.000 description 3
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
239000005695 Ammonium acetate Substances 0.000 description 3
241000400611 Eucalyptus deanei Species 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
235000019257 ammonium acetate Nutrition 0.000 description 3
229940043376 ammonium acetate Drugs 0.000 description 3
239000002260 anti-inflammatory agent Substances 0.000 description 3
239000000337 buffer salt Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229960001334 corticosteroids Drugs 0.000 description 3
238000000132 electrospray ionisation Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229940014259 gelatin Drugs 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 3
RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
239000012266 salt solution Substances 0.000 description 3
239000012047 saturated solution Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000007921 spray Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000008107 starch Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
KQCFQSMHNZFZCQ-MCDZGGTQSA-N (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol N-ethylformamide Chemical compound CCNC=O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KQCFQSMHNZFZCQ-MCDZGGTQSA-N 0.000 description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 2
PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
229910006074 SO2NH2 Inorganic materials 0.000 description 2
239000005708 Sodium hypochlorite Substances 0.000 description 2
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
239000013566 allergen Substances 0.000 description 2
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
229940063655 aluminum stearate Drugs 0.000 description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
230000002924 anti-infective effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
229940127218 antiplatelet drug Drugs 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000003240 coconut oil Substances 0.000 description 2
235000019864 coconut oil Nutrition 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
ZXZQXWVPGASIQP-UHFFFAOYSA-N ethyl 2-methylpropanimidate Chemical compound CCOC(=N)C(C)C ZXZQXWVPGASIQP-UHFFFAOYSA-N 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
238000007327 hydrogenolysis reaction Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
125000000842 isoxazolyl group Chemical group 0.000 description 2
NWYYWIJOWOLJNR-RXMQYKEDSA-N l-valinol Chemical compound CC(C)[C@H](N)CO NWYYWIJOWOLJNR-RXMQYKEDSA-N 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
239000006210 lotion Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
125000002971 oxazolyl group Chemical group 0.000 description 2
PQPFFKCJENSZKL-UHFFFAOYSA-N pentan-3-amine Chemical compound CCC(N)CC PQPFFKCJENSZKL-UHFFFAOYSA-N 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000000106 platelet aggregation inhibitor Substances 0.000 description 2
235000011181 potassium carbonates Nutrition 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000000376 reactant Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000010802 sludge Substances 0.000 description 2
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
XBPZWOVVTVUFCD-IMIIHFCZSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]-5-(1-ethyl-1,2,4-triazol-3-yl)oxolane-3,4-diol Chemical compound CCN1C=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(Cl)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 XBPZWOVVTVUFCD-IMIIHFCZSA-N 0.000 description 1
NYIWJJRXORTCSV-JLFWUPFSSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]-5-(3-propan-2-yl-1h-1,2,4-triazol-5-yl)oxolane-3,4-diol Chemical compound CC(C)C1=NNC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(Cl)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 NYIWJJRXORTCSV-JLFWUPFSSA-N 0.000 description 1
OTMRPCQQYKDZGP-IMIIHFCZSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)oxolane-3,4-diol Chemical compound O1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(Cl)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 OTMRPCQQYKDZGP-IMIIHFCZSA-N 0.000 description 1
YIJRBFFHGMMYQP-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(pentan-3-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NC(CC)CC)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YIJRBFFHGMMYQP-IDTAVKCVSA-N 0.000 description 1
BIFZVTXGRNIYJQ-YLGWJBDOSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-morpholin-4-ylethylamino)purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.O1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCN4CCOCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 BIFZVTXGRNIYJQ-YLGWJBDOSA-N 0.000 description 1
QUECGMGWGMRRRQ-YLGWJBDOSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-morpholin-4-ylethylamino)purin-9-yl]-5-(5-ethyl-1h-1,2,4-triazol-3-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.N1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCN4CCOCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 QUECGMGWGMRRRQ-YLGWJBDOSA-N 0.000 description 1
JNGREZTVPUTJNM-ZQIFAIMYSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.O1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCN4CCCCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 JNGREZTVPUTJNM-ZQIFAIMYSA-N 0.000 description 1
CBLXUKBLGILVIC-ZQIFAIMYSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-pyridin-2-ylethylamino)purin-9-yl]-5-(5-ethyl-1h-1,2,4-triazol-3-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.N1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCC=4N=CC=CC=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 CBLXUKBLGILVIC-ZQIFAIMYSA-N 0.000 description 1
IUFRTQRCJKJFGV-VAQUGZGVSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-(2-pyrrolidin-1-ylethylamino)purin-9-yl]-5-(5-methyl-1h-1,2,4-triazol-3-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.N1C(C)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCN4CCCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 IUFRTQRCJKJFGV-VAQUGZGVSA-N 0.000 description 1
BOPSSCHOYCFONA-YLGWJBDOSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-[2-(1-methylimidazol-4-yl)ethylamino]purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.O1C(CC)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCC=4N=CN(C)C=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 BOPSSCHOYCFONA-YLGWJBDOSA-N 0.000 description 1
VJOPRQDMBYDDPT-VAQUGZGVSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)-2-[2-(1-methylimidazol-4-yl)ethylamino]purin-9-yl]-5-(5-methyl-1h-1,2,4-triazol-3-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.N1C(C)=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(NCCC=4N=CN(C)C=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O)=N1 VJOPRQDMBYDDPT-VAQUGZGVSA-N 0.000 description 1
HTQVXAKTASCSHR-IMIIHFCZSA-N (2r,3r,4s,5s)-2-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]-5-(5-ethyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol Chemical compound O1C(CC)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(Cl)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 HTQVXAKTASCSHR-IMIIHFCZSA-N 0.000 description 1
LOXOCXZWABXHDK-UGCAPWQASA-N (2r,3r,4s,5s)-2-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]-5-(5-methyl-1,3,4-thiadiazol-2-yl)oxolane-3,4-diol Chemical compound S1C(C)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(Cl)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 LOXOCXZWABXHDK-UGCAPWQASA-N 0.000 description 1
MUZQOPSLRQIIBU-CVXDAYKESA-N (2r,3r,4s,5s)-2-[2-chloro-6-(pentan-3-ylamino)purin-9-yl]-5-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol Chemical compound O1C([C@H]2O[C@H]([C@@H]([C@@H]2O)O)N2C=3N=C(Cl)N=C(C=3N=C2)NC(CC)CC)=NN=C1C1CC1 MUZQOPSLRQIIBU-CVXDAYKESA-N 0.000 description 1
WHKXXERQWARIAA-YLGWJBDOSA-N (2r,3r,4s,5s)-2-[6-(2,2-diphenylethylamino)-2-(2-morpholin-4-ylethylamino)purin-9-yl]-5-(5-ethyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.O1C(CC)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(NCCN4CCOCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 WHKXXERQWARIAA-YLGWJBDOSA-N 0.000 description 1
DBBDAOHSEVBAOB-ZQIFAIMYSA-N (2r,3r,4s,5s)-2-[6-(2,2-diphenylethylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]-5-(5-ethyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.O1C(CC)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(NCCN4CCCCC4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 DBBDAOHSEVBAOB-ZQIFAIMYSA-N 0.000 description 1
JSJOVATUTRUSFP-ZQIFAIMYSA-N (2r,3r,4s,5s)-2-[6-(2,2-diphenylethylamino)-2-(2-pyridin-2-ylethylamino)purin-9-yl]-5-(5-ethyl-1,3,4-oxadiazol-2-yl)oxolane-3,4-diol;formic acid Chemical compound OC=O.O1C(CC)=NN=C1[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC(NCCC=4N=CC=CC=4)=NC(NCC(C=4C=CC=CC=4)C=4C=CC=CC=4)=C3N=C2)O1 JSJOVATUTRUSFP-ZQIFAIMYSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
DRNVQNGKOQZGMR-PKIKSRDPSA-N (3aR,4R,6S,6aS)-4-methoxy-2,2-dimethyl-N-(2-oxopropyl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide Chemical compound O=C(CNC(=O)[C@H]1O[C@H]([C@@H]2OC(O[C@@H]21)(C)C)OC)C DRNVQNGKOQZGMR-PKIKSRDPSA-N 0.000 description 1
ZVKHSTMHDBPCMU-VWVCVJEOSA-N (3aR,4R,6S,6aS)-N-(2-hydroxypropyl)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide Chemical compound OC(CNC(=O)[C@H]1O[C@H]([C@@H]2OC(O[C@@H]21)(C)C)OC)C ZVKHSTMHDBPCMU-VWVCVJEOSA-N 0.000 description 1
SLWMKMAZXAQUTQ-FBROZUCGSA-N (3ar,4r,6r,6ar)-4-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]-n'-hydroxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboximidamide Chemical compound N1=C(Cl)N=C2N([C@H]3[C@H]4[C@@H]([C@H](O3)\C(N)=N\O)OC(O4)(C)C)C=NC2=C1NCC(C=1C=CC=CC=1)C1=CC=CC=C1 SLWMKMAZXAQUTQ-FBROZUCGSA-N 0.000 description 1
IZGZCDXQVIRFKU-FBROZUCGSA-N (3ar,4r,6s,6as)-4-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carbohydrazide Chemical compound N1=C(Cl)N=C2N([C@H]3[C@H]4[C@@H]([C@H](O3)C(=O)NN)OC(O4)(C)C)C=NC2=C1NCC(C=1C=CC=CC=1)C1=CC=CC=C1 IZGZCDXQVIRFKU-FBROZUCGSA-N 0.000 description 1
QJISGLSLTPENML-FBROZUCGSA-N (3ar,4r,6s,6as)-4-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide Chemical compound N1=C(Cl)N=C2N([C@H]3[C@H]4[C@@H]([C@H](O3)C(N)=O)OC(O4)(C)C)C=NC2=C1NCC(C=1C=CC=CC=1)C1=CC=CC=C1 QJISGLSLTPENML-FBROZUCGSA-N 0.000 description 1
GVBBJEZFJLZLPV-OZTPJHRESA-N (3ar,4r,6s,6as)-4-[2-chloro-6-(pentan-3-ylamino)purin-9-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxylic acid Chemical compound CCC(CC)NC1=NC(Cl)=NC2=C1N=CN2[C@H]1[C@@H]2OC(C)(C)O[C@@H]2[C@@H](C(O)=O)O1 GVBBJEZFJLZLPV-OZTPJHRESA-N 0.000 description 1
RCCAMDILSVZUFY-VCWZQCKKSA-N (3r,4s,5r)-5-(5-ethyl-1,2-oxazol-3-yl)oxolane-2,3,4-triol Chemical compound O1C(CC)=CC([C@@H]2[C@H]([C@@H](O)C(O)O2)O)=N1 RCCAMDILSVZUFY-VCWZQCKKSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
125000006648 (C1-C8) haloalkyl group Chemical group 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
NHMPBWJFSNZZLO-DDHJBXDOSA-N 1-[(3ar,4r,6r,6ar)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]-1-hydroxyiminopentan-3-one Chemical compound O1C(C)(C)O[C@@H]2[C@@H](C(=NO)CC(=O)CC)O[C@@H](OC)[C@@H]21 NHMPBWJFSNZZLO-DDHJBXDOSA-N 0.000 description 1
HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
WGMHMVLZFAJNOT-UHFFFAOYSA-N 1-ethoxyethylideneazanium;chloride Chemical compound [Cl-].CCOC(C)=[NH2+] WGMHMVLZFAJNOT-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
VUZNLSBZRVZGIK-UHFFFAOYSA-N 2,2,6,6-Tetramethyl-1-piperidinol Chemical compound CC1(C)CCCC(C)(C)N1O VUZNLSBZRVZGIK-UHFFFAOYSA-N 0.000 description 1
NDVMCQUOSYOQMZ-UHFFFAOYSA-N 2,2-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)C(C(N)=O)[Si](C)(C)C NDVMCQUOSYOQMZ-UHFFFAOYSA-N 0.000 description 1
HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
RXMTUVIKZRXSSM-UHFFFAOYSA-N 2,2-diphenylethanamine Chemical compound C=1C=CC=CC=1C(CN)C1=CC=CC=C1 RXMTUVIKZRXSSM-UHFFFAOYSA-N 0.000 description 1
125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
FQLGGDUOFSWKMS-UHFFFAOYSA-N 2-(1-methylimidazol-4-yl)ethanamine;hydrochloride Chemical compound Cl.CN1C=NC(CCN)=C1 FQLGGDUOFSWKMS-UHFFFAOYSA-N 0.000 description 1
HFACYWDPMNWMIW-UHFFFAOYSA-N 2-cyclohexylethanamine Chemical compound NCCC1CCCCC1 HFACYWDPMNWMIW-UHFFFAOYSA-N 0.000 description 1
IEVJVQXLBZUEMH-UHFFFAOYSA-N 2-piperidin-2-ylethanamine Chemical compound NCCC1CCCCN1 IEVJVQXLBZUEMH-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
QJNLUNBGDFUULX-UHFFFAOYSA-N 4-n,4-n'-dimethyl-3h-pyridine-4,4-diamine Chemical compound CNC1(NC)CC=NC=C1 QJNLUNBGDFUULX-UHFFFAOYSA-N 0.000 description 1
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
101150078577 Adora2b gene Proteins 0.000 description 1
102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
NEKUOWADVQSFGD-ZOXXBUSZSA-N C(=O)O.N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)C(C)C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C(=O)O.N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)C(C)C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 NEKUOWADVQSFGD-ZOXXBUSZSA-N 0.000 description 1
JAMFLMYPFFDCOT-NYFSBHSYSA-N C(=O)O.N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C(=O)O.N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 JAMFLMYPFFDCOT-NYFSBHSYSA-N 0.000 description 1
FWVBJIYIGYEPFP-GVROIHNXSA-N C(=O)O.N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C(=O)O.N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C1=NN=C(N1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 FWVBJIYIGYEPFP-GVROIHNXSA-N 0.000 description 1
CEUMKXCZTAEZEF-GVROIHNXSA-N C(=O)O.N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C=1OC(=NN1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C(=O)O.N[C@@H]1CC[C@H](CC1)NC1=NC(=C2N=CN(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C=1OC(=NN1)CC)NCC(C1=CC=CC=C1)C1=CC=CC=C1 CEUMKXCZTAEZEF-GVROIHNXSA-N 0.000 description 1
GRGNBYFSGQZSFQ-KYEUVZBBSA-N C(=O)O[C@H]1[C@@H](O[C@@H]([C@@H]1OC=O)C1=NN(C=N1)CC)N1C2=NC(=NC(=C2N=C1)NCC(C1=CC=CC=C1)C1=CC=CC=C1)N[C@@H]1CC[C@H](CC1)N Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@@H]1OC=O)C1=NN(C=N1)CC)N1C2=NC(=NC(=C2N=C1)NCC(C1=CC=CC=C1)C1=CC=CC=C1)N[C@@H]1CC[C@H](CC1)N GRGNBYFSGQZSFQ-KYEUVZBBSA-N 0.000 description 1
NRPJJYQVZRISAX-JTNFPWQOSA-N C(=O)O[C@H]1[C@@H](O[C@@H]([C@H]1OC=O)C=1OC(=NN=1)C1CC1)N1C2=NC(=NC(=C2N=C1)NC(CC)CC)NCCC1CCCCC1 Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@H]1OC=O)C=1OC(=NN=1)C1CC1)N1C2=NC(=NC(=C2N=C1)NC(CC)CC)NCCC1CCCCC1 NRPJJYQVZRISAX-JTNFPWQOSA-N 0.000 description 1
HGMUQMTXNHIVHU-PUVPXUBESA-N C(=O)O[C@H]1[C@@H](O[C@@H]([C@H]1OC=O)C=1OC(=NN=1)C1CC1)N1C2=NC(=NC(=C2N=C1)NC(CC)CC)N[C@@H]1CC[C@H](CC1)N Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@H]1OC=O)C=1OC(=NN=1)C1CC1)N1C2=NC(=NC(=C2N=C1)NC(CC)CC)N[C@@H]1CC[C@H](CC1)N HGMUQMTXNHIVHU-PUVPXUBESA-N 0.000 description 1
PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
206010012434 Dermatitis allergic Diseases 0.000 description 1
206010051392 Diapedesis Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
244000166102 Eucalyptus leucoxylon Species 0.000 description 1
235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
206010051841 Exposure to allergen Diseases 0.000 description 1
206010073306 Exposure to radiation Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000012895 Gastric disease Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
238000005684 Liebig rearrangement reaction Methods 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229910019213 POCl3 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108700020962 Peroxidase Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000018569 Respiratory Tract disease Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
QRKAXEVBYOVJST-JPYYHWIRSA-N [(2R,3S,4R,5R)-2-(5-ethyl-1,2-oxazol-3-yl)-4-formyloxy-5-[6-(pentan-3-ylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]oxolan-3-yl] formate Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@@H]1OC=O)C1=NOC(=C1)CC)N1C2=NC(=NC(=C2N=C1)NC(CC)CC)NCCN1CCCCC1 QRKAXEVBYOVJST-JPYYHWIRSA-N 0.000 description 1
QSLYMJKUUYXEGU-DZNDNOMISA-N [(2R,3S,4R,5R)-5-[2-(2-aminoethylamino)-6-(2,2-diphenylethylamino)purin-9-yl]-2-(5-ethyl-1,2,4-oxadiazol-3-yl)-4-formyloxyoxolan-3-yl] formate Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@@H]1OC=O)C1=NOC(=N1)CC)N1C2=NC(=NC(=C2N=C1)NCC(C1=CC=CC=C1)C1=CC=CC=C1)NCCN QSLYMJKUUYXEGU-DZNDNOMISA-N 0.000 description 1
CFPKUSKDMKHQSP-KVOHOPFUSA-N [(2R,3S,4R,5R)-5-[6-(2,2-diphenylethylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]-2-(1-ethyl-1,2,4-triazol-3-yl)-4-formyloxyoxolan-3-yl] formate Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@@H]1OC=O)C1=NN(C=N1)CC)N1C2=NC(=NC(=C2N=C1)NCC(C1=CC=CC=C1)C1=CC=CC=C1)NCCN1CCCCC1 CFPKUSKDMKHQSP-KVOHOPFUSA-N 0.000 description 1
WDRHNBHRXJGNSB-KVOHOPFUSA-N [(2R,3S,4R,5R)-5-[6-(2,2-diphenylethylamino)-2-(2-pyridin-2-ylethylamino)purin-9-yl]-2-(1-ethyl-1,2,4-triazol-3-yl)-4-formyloxyoxolan-3-yl] formate Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@@H]1OC=O)C1=NN(C=N1)CC)N1C2=NC(=NC(=C2N=C1)NCC(C1=CC=CC=C1)C1=CC=CC=C1)NCCC1=NC=CC=C1 WDRHNBHRXJGNSB-KVOHOPFUSA-N 0.000 description 1
VAUCDKRHGXEOFC-CLWMVSBGSA-N [(2R,3S,4R,5R)-5-[6-(2,2-diphenylethylamino)-2-[2-(1-methylimidazol-4-yl)ethylamino]purin-9-yl]-2-(1-ethyl-1,2,4-triazol-3-yl)-4-formyloxyoxolan-3-yl] formate Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@@H]1OC=O)C1=NN(C=N1)CC)N1C2=NC(=NC(=C2N=C1)NCC(C1=CC=CC=C1)C1=CC=CC=C1)NCCC=1N=CN(C=1)C VAUCDKRHGXEOFC-CLWMVSBGSA-N 0.000 description 1
KQYYDKWEIOUPSP-SBZFUYPRSA-N [(2S,3S,4R,5R)-2-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-4-formyloxy-5-[2-[2-(1-methylimidazol-4-yl)ethylamino]-6-(pentan-3-ylamino)purin-9-yl]oxolan-3-yl] formate Chemical compound C(=O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC=O)N1C2=NC(=NC(=C2N=C1)NC(CC)CC)NCCC=1N=CN(C1)C)C=1OC(=NN1)C1CC1 KQYYDKWEIOUPSP-SBZFUYPRSA-N 0.000 description 1
SXTPWJIPUQJLPB-XZWCOCNFSA-N [(2S,3S,4R,5R)-5-[2-(cyclopentylamino)-6-(pentan-3-ylamino)purin-9-yl]-2-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-4-formyloxyoxolan-3-yl] formate Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@H]1OC=O)C=1OC(=NN1)C1CC1)N1C2=NC(=NC(=C2N=C1)NC(CC)CC)NC1CCCC1 SXTPWJIPUQJLPB-XZWCOCNFSA-N 0.000 description 1
VVWHFJZQZPKPNT-YQQRZDPSSA-N [(2S,3S,4R,5R)-5-[6-(2,2-diphenylethylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]-4-formyloxy-2-(5-methyl-1,3,4-thiadiazol-2-yl)oxolan-3-yl] formate Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@H]1OC=O)C=1SC(=NN1)C)N1C2=NC(=NC(=C2N=C1)NCC(C1=CC=CC=C1)C1=CC=CC=C1)NCCN1CCCCC1 VVWHFJZQZPKPNT-YQQRZDPSSA-N 0.000 description 1
DSSJQXPQAYJLJE-VGBJTSDXSA-N [(2S,3S,4R,5R)-5-[6-(2,2-diphenylethylamino)-2-[2-(1-methylimidazol-4-yl)ethylamino]purin-9-yl]-4-formyloxy-2-(5-methyl-1,3,4-thiadiazol-2-yl)oxolan-3-yl] formate Chemical compound C(=O)O[C@H]1[C@@H](O[C@@H]([C@H]1OC=O)C=1SC(=NN=1)C)N1C2=NC(=NC(=C2N=C1)NCC(C1=CC=CC=C1)C1=CC=CC=C1)NCCC=1N=CN(C=1)C DSSJQXPQAYJLJE-VGBJTSDXSA-N 0.000 description 1
STOAKQCDXXHAGW-CBNXCZCTSA-N [(2r,3r,4r)-4,5-diacetyloxy-2-(5-ethyl-1,2-oxazol-3-yl)oxolan-3-yl] acetate Chemical compound O1C(CC)=CC([C@@H]2[C@H]([C@@H](OC(C)=O)C(OC(C)=O)O2)OC(C)=O)=N1 STOAKQCDXXHAGW-CBNXCZCTSA-N 0.000 description 1
PYXZXWLFAMZVPY-SDBHATRESA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-(2,6-dichloropurin-9-yl)oxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC(Cl)=NC(Cl)=C2N=C1 PYXZXWLFAMZVPY-SDBHATRESA-N 0.000 description 1
KQVSRIJPLDMUSG-VMUDFCTBSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(2,6-dichloropurin-9-yl)-2-(5-ethyl-1,2-oxazol-3-yl)oxolan-3-yl] acetate Chemical compound O1C(CC)=CC([C@@H]2[C@H]([C@@H](OC(C)=O)[C@@H](O2)N2C3=NC(Cl)=NC(Cl)=C3N=C2)OC(C)=O)=N1 KQVSRIJPLDMUSG-VMUDFCTBSA-N 0.000 description 1
NWFAQPDDAIRXHL-JPAWQOSXSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-[2-chloro-6-(pentan-3-ylamino)purin-9-yl]-2-(5-ethyl-1,2-oxazol-3-yl)oxolan-3-yl] acetate Chemical compound C=1([C@H]2O[C@H]([C@@H]([C@@H]2OC(C)=O)OC(C)=O)N2C=3N=C(Cl)N=C(C=3N=C2)NC(CC)CC)C=C(CC)ON=1 NWFAQPDDAIRXHL-JPAWQOSXSA-N 0.000 description 1
PYAJBXKITOBGFK-RSOWOKRSSA-N [(2s,3s,4r,5r)-2-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-4-formyloxy-5-[6-(pentan-3-ylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]oxolan-3-yl] formate Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](OC=O)[C@H](O3)C=3OC(=NN=3)C3CC3)OC=O)C=NC=2C(NC(CC)CC)=NC=1NCCN1CCCCC1 PYAJBXKITOBGFK-RSOWOKRSSA-N 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
239000003121 adenosine kinase inhibitor Substances 0.000 description 1
150000003838 adenosines Chemical class 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000002253 anti-ischaemic effect Effects 0.000 description 1
230000003243 anti-lipolytic effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
229950000210 beclometasone dipropionate Drugs 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000004044 bronchoconstricting agent Substances 0.000 description 1
230000003435 bronchoconstrictive effect Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
230000005792 cardiovascular activity Effects 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
JFYKIEHOOZWARC-UHFFFAOYSA-N cyclopropanecarbohydrazide Chemical compound NNC(=O)C1CC1 JFYKIEHOOZWARC-UHFFFAOYSA-N 0.000 description 1
YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229960004132 diethyl ether Drugs 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
ATZIPACKTBIFAX-UHFFFAOYSA-N ethyl propanimidate;hydrochloride Chemical compound Cl.CCOC(=N)CC ATZIPACKTBIFAX-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
229960001022 fenoterol Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
229960002848 formoterol Drugs 0.000 description 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
208000024364 idiopathic hypereosinophilic syndrome Diseases 0.000 description 1
125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
229940102253 isopropanolamine Drugs 0.000 description 1
238000005304 joining Methods 0.000 description 1
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000004200 microcrystalline wax Substances 0.000 description 1
235000019808 microcrystalline wax Nutrition 0.000 description 1
150000007522 mineralic acids Chemical group 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
229960002744 mometasone furoate Drugs 0.000 description 1
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
108010031345 placental alkaline phosphatase Proteins 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
UVTSXMRYLRNGSD-UHFFFAOYSA-N propanehydrazide;2,2,2-trifluoroacetic acid Chemical compound CCC(=O)NN.OC(=O)C(F)(F)F UVTSXMRYLRNGSD-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
150000003290 ribose derivatives Chemical class 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
235000020374 simple syrup Nutrition 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
208000018556 stomach disease Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
238000010998 test method Methods 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
229960002117 triamcinolone acetonide Drugs 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

HR20000895A 1998-06-23 2000-12-21 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives HRP20000895A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9813565.0A GB9813565D0 (en)	1998-06-23	1998-06-23	Chemical compounds
PCT/EP1999/004267 WO1999067264A1 (en)	1998-06-23	1999-06-23	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Publications (1)

Publication Number	Publication Date
HRP20000895A2 true HRP20000895A2 (en)	2001-10-31

Family

ID=10834254

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20000895A HRP20000895A2 (en)	1998-06-23	2000-12-21	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Country Status (26)

Country	Link
EP (1)	EP1090023B1 (is)
JP (1)	JP2002518511A (is)
KR (1)	KR20010071570A (is)
CN (1)	CN1313860A (is)
AP (1)	AP2000002013A0 (is)
AT (1)	ATE249474T1 (is)
AU (1)	AU758979B2 (is)
BR (1)	BR9911488A (is)
CA (1)	CA2335758A1 (is)
DE (1)	DE69911207D1 (is)
EA (1)	EA200001223A1 (is)
EE (1)	EE200000764A (is)
GB (1)	GB9813565D0 (is)
HR (1)	HRP20000895A2 (is)
HU (1)	HUP0102454A3 (is)
ID (1)	ID28219A (is)
IL (1)	IL140285A0 (is)
IS (1)	IS5774A (is)
NO (1)	NO20006521L (is)
NZ (1)	NZ508918A (is)
PL (1)	PL345097A1 (is)
SK (1)	SK19532000A3 (is)
TR (1)	TR200100411T2 (is)
WO (1)	WO1999067264A1 (is)
YU (1)	YU81000A (is)
ZA (1)	ZA200007515B (is)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6514949B1 (en)	1994-07-11	2003-02-04	University Of Virginia Patent Foundation	Method compositions for treating the inflammatory response
US7378400B2 (en)	1999-02-01	2008-05-27	University Of Virginia Patent Foundation	Method to reduce an inflammatory response from arthritis
US6232297B1 (en)	1999-02-01	2001-05-15	University Of Virginia Patent Foundation	Methods and compositions for treating inflammatory response
US7427606B2 (en)	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
US6670334B2 (en)	2001-01-05	2003-12-30	University Of Virginia Patent Foundation	Method and compositions for treating the inflammatory response
GB0104555D0 (en) *	2001-02-23	2001-04-11	Glaxo Group Ltd	New Therapeutic method
NZ532062A (en)	2001-10-01	2006-09-29	Univ Virginia	2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
TWI346109B (en)	2004-04-30	2011-08-01	Otsuka Pharma Co Ltd	4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006028618A1 (en)	2004-08-02	2006-03-16	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006015357A2 (en)	2004-08-02	2006-02-09	University Of Virginia Patent Foundation	2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0500785D0 (en) *	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
AR058104A1 (es)	2005-10-21	2008-01-23	Novartis Ag	Compuestos organicos
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
JP2010504933A (ja)	2006-09-29	2010-02-18	ノバルティスアーゲー	Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
EP2089393A1 (en)	2006-10-30	2009-08-19	Novartis AG	Heterocyclic compounds as antiinflammatory agents
PL2231642T3 (pl)	2008-01-11	2014-04-30	Novartis Ag	Pirymidyny jako inhibitory kinazy
US20110281917A1 (en)	2009-01-29	2011-11-17	Darrin Stuart	Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en)	2009-08-12	2012-03-01	Novartis Ag	Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en)	2009-08-17	2012-03-29	Intellikine Inc	Heterocyclic compounds and uses thereof
JP5775871B2 (ja)	2009-08-20	2015-09-09	ノバルティスアーゲー	ヘテロ環式オキシム化合物
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
WO2012107500A1 (en)	2011-02-10	2012-08-16	Novartis Ag	[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
WO2012116217A1 (en)	2011-02-25	2012-08-30	Irm Llc	Compounds and compositions as trk inhibitors
JP5957526B2 (ja)	2011-09-15	2016-07-27	ノバルティスアーゲー	チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
WO2013078440A2 (en)	2011-11-23	2013-05-30	Intellikine, Llc	Enhanced treatment regimens using mtor inhibitors
CN110507654A (zh)	2012-04-03	2019-11-29	诺华有限公司	有酪氨酸激酶抑制剂的组合产品和其应用
JP2016512835A (ja)	2013-03-15	2016-05-09	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせ及びそれらの使用
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
US10195208B2 (en)	2014-07-31	2019-02-05	Novartis Ag	Combination therapy
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9301000D0 (en) *	1993-01-20	1993-03-10	Glaxo Group Ltd	Chemical compounds
AU3255097A (en) *	1996-07-05	1998-02-02	Novo Nordisk A/S	Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
TW528755B (en) *	1996-12-24	2003-04-21	Glaxo Group Ltd	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (sh) *	1998-01-31	2003-01-31	Glaxo Group Limited	Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) *	1998-02-14	2000-12-26	Glaxo Group Ltd	Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol

1998
- 1998-06-23 GB GBGB9813565.0A patent/GB9813565D0/en not_active Ceased
1999
- 1999-06-23 AP APAP/P/2000/002013A patent/AP2000002013A0/en unknown
- 1999-06-23 DE DE69911207T patent/DE69911207D1/de not_active Expired - Lifetime
- 1999-06-23 JP JP2000555915A patent/JP2002518511A/ja active Pending
- 1999-06-23 PL PL99345097A patent/PL345097A1/xx unknown
- 1999-06-23 EE EEP200000764A patent/EE200000764A/xx unknown
- 1999-06-23 EP EP99934530A patent/EP1090023B1/en not_active Expired - Lifetime
- 1999-06-23 CA CA002335758A patent/CA2335758A1/en not_active Abandoned
- 1999-06-23 EA EA200001223A patent/EA200001223A1/ru unknown
- 1999-06-23 AT AT99934530T patent/ATE249474T1/de not_active IP Right Cessation
- 1999-06-23 WO PCT/EP1999/004267 patent/WO1999067264A1/en not_active Application Discontinuation
- 1999-06-23 KR KR1020007014622A patent/KR20010071570A/ko not_active Application Discontinuation
- 1999-06-23 AU AU50281/99A patent/AU758979B2/en not_active Ceased
- 1999-06-23 CN CN99809865A patent/CN1313860A/zh active Pending
- 1999-06-23 NZ NZ508918A patent/NZ508918A/xx unknown
- 1999-06-23 ID IDW20010187A patent/ID28219A/id unknown
- 1999-06-23 HU HU0102454A patent/HUP0102454A3/hu unknown
- 1999-06-23 YU YU81000A patent/YU81000A/sh unknown
- 1999-06-23 BR BR9911488-7A patent/BR9911488A/pt not_active IP Right Cessation
- 1999-06-23 SK SK1953-2000A patent/SK19532000A3/sk unknown
- 1999-06-23 TR TR2001/00411T patent/TR200100411T2/xx unknown
- 1999-06-23 IL IL14028599A patent/IL140285A0/xx unknown
2000
- 2000-12-14 ZA ZA200007515A patent/ZA200007515B/xx unknown
- 2000-12-15 IS IS5774A patent/IS5774A/is unknown
- 2000-12-20 NO NO20006521A patent/NO20006521L/no not_active Application Discontinuation
- 2000-12-21 HR HR20000895A patent/HRP20000895A2/hr not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU758979B2 (en)	2003-04-03
EA200001223A1 (ru)	2001-10-22
YU81000A (sh)	2003-10-31
KR20010071570A (ko)	2001-07-28
EP1090023A1 (en)	2001-04-11
ID28219A (id)	2001-05-10
TR200100411T2 (tr)	2001-07-23
NO20006521L (no)	2001-02-22
DE69911207D1 (de)	2003-10-16
ATE249474T1 (de)	2003-09-15
EE200000764A (et)	2002-04-15
ZA200007515B (en)	2001-12-14
CN1313860A (zh)	2001-09-19
GB9813565D0 (en)	1998-08-19
HUP0102454A3 (en)	2003-01-28
JP2002518511A (ja)	2002-06-25
BR9911488A (pt)	2001-03-20
NZ508918A (en)	2003-03-28
NO20006521D0 (no)	2000-12-20
HUP0102454A2 (hu)	2002-01-28
CA2335758A1 (en)	1999-12-29
AU5028199A (en)	2000-01-10
IS5774A (is)	2000-12-15
IL140285A0 (en)	2002-02-10
PL345097A1 (en)	2001-12-03
AP2000002013A0 (en)	2000-12-31
WO1999067264A1 (en)	1999-12-29
SK19532000A3 (sk)	2001-11-06
EP1090023B1 (en)	2003-09-10

Legal Events

Date	Code	Title	Description
2001-10-31	A1OB	Publication of a patent application
2002-02-11	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2003-04-23	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20030423 Year of fee payment: 5
2008-11-17	OBST	Application withdrawn

Publication	Publication Date	Title
HRP20000895A2 (en)	2001-10-31	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6610665B1 (en)	2003-08-26	2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives
US6534486B1 (en)	2003-03-18	2-(purin-9-yl)-Tetrahydrofuran-3,4-diol derivatives
JP3933870B2 (ja)	2007-06-20	２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
EP1090020B1 (en)	2003-11-05	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP4156035B2 (ja)	2008-09-24	２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
KR20010034473A (ko)	2001-04-25	2-(퓨린-9-일)-테트라히드로퓨란-3,4-디올 유도체
MXPA00012895A (en)	2001-09-07	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CZ20004870A3 (cs)	2001-06-13	2 (Purin 9 yl) tetrahydrofuran 3,4 diolové deriváty
MXPA00007793A (en)	2001-11-21	2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives
MXPA00012926A (en)	2002-05-09	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CZ20002787A3 (cs)	2001-04-11	2-(purin-9-yl)-tetrahydrofuran-3,4-diolové deriváty
CZ20002974A3 (cs)	2001-05-16	2-(purin-9-yl)-tetrahydrofuran-3,4-diolové deriváty